CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 438 enrolled
Drug / intervention
Alogliptin +4 moredrug
Likely dose
Alogliptin 6.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01263496
NCT01263496Phase 2Completed
CompareCT.gov

A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan.

Takeda·interventional·Posted Dec 20, 2010·Updated Feb 3, 2012

In Brief

A Phase 2 clinical trial evaluating Alogliptin and Voglibose for Type 2 Diabetes Mellitus. Completed, enrolled 438 participants.

Detailed Summary

The purpose of this study was to evaluate the long-term safety and efficacy of SYR-322, once daily (QD), to an α-glucosidase inhibitor, three times daily (TID), administered for 40 consecutive weeks in participants who completed a phase 2 dose-ranging study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2010
Enrollment StartMay 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.5 years ago

Interventions

Alogliptindrug

Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.

Alogliptindrug

Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.

Alogliptindrug

Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.

Alogliptindrug

Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.

Voglibosedrug

Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.